New Product Line is the Only FDA-Cleared Cleansing and Debridement System Containing CHG; Delivers Distinct Benefits
ATLANTA--(BUSINESS WIRE)-- Association for Professionals in Infection Control and Epidemiology (APIC) members attending APIC 2011 will have the opportunity to be introduced to IrriSept® O.R. and IrriSept® (www.irrisept.com), the first and only FDA-cleared cleansing and debridement system containing chlorhexidine gluconate (CHG). The 0.05 percent CHG concentration in IrriSept has been shown effective in laboratory testing against a variety of bacteria and fungi, including Staph and methicillin-resistant Staphylococcus aureus (MRSA).1,2 The solution has passed FDA-required tests for cytotoxicity, skin irritation and immune (allergic) response.3
Healthcare providers finally have an alternative to saline irrigation and can now use IrriSept O.R. during surgical procedures as a final rinse before closure, or for existing surgical site infections (SSIs). IrriSept also can be used on a variety of other wounds, including abscesses, skin and soft tissue infections (SSTIs), deep traumatic wounds, delayed closures, burns, wound dehiscence and pilonidal cysts.
In addition, the product is:
- Fast-acting: In log-reduction studies, exposure to IrriSept solution resulted in >99.98 percent reduction at one minute for MRSA and Pseudomonas.4
- Persistent: The IrriSept 0.05 percent CHG solution destroyed and inhibited MRSA and Coag-neg Staph grown on lab samples for 14 days.
- Versatile: IrriSept features a series of three unique applicators, designed to help cleanse and debride wounds.
“APIC 2011 provides a tremendous opportunity for us to showcase IrriSept,” says IrriMax Chief Executive Officer Gareth Clarke, formerly the driving force behind the global expansion of Biogel® gloves. “Because infection prevention is a major concern for APIC members, we are eager to introduce healthcare providers to the merits of the IrriSept system, knowing they will recognize its distinct benefits.” Clarke adds, “I believe this new product has the potential to improve patient outcomes, decrease hospital lengths of stay and help medical facilities address infection-related challenges.”
APIC 2011 is the most comprehensive annual conference dedicated to infection prevention clinical education, providing opportunities to learn about new science, technologies, advances, and products that can strengthen infection prevention and control programs. It also features the world’s largest exhibit hall devoted to infection prevention, displaying the latest in innovative products and services. This year’s event will be held June 27-29 in Baltimore.
Founded in 2003, IrriMax® Corporation develops and markets irrigation solutions using a patented, innovative delivery method that produces unmatched efficacy and safety. The medical device company’s goal is to improve patient outcomes by treating and preventing infections, as well as to increase the safety of healthcare workers. Its flagship product, IrriSept®, is the first and only FDA-cleared irrigation system containing CHG. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information, visit www.irrisept.com.
1 Laboratory Testing Records per USP <51>, Antimicrobial Effectiveness Testing, on file at IrriMax Corporation
2 Laboratory Testing Records, “Chlorhexidine Gluconate (CHG) Bacterial Study Report,” on file at IrriMax Corporation
3 Biocompatibility compliance tests completed per FDA’s Blue Book Memorandum G95-1 and ISO 10993-1, Biological Evaluation of Medical Devices, on file at IrriMax Corporation
4 Study on file at IrriMax Corporation
For IrriMax Corporation
Debra Patterson, 404-843-8786
KEYWORDS: United States North America Georgia Maryland
INDUSTRY KEYWORDS: Surgery Health Hospitals Infectious Diseases Other Health Medical Supplies